Idiopathic aplastic pancytopenia is an uncommon disease in dogs which results in pancytopenia and for which an immune-mediated etiology is suspected. A small number of affected dogs reported in the veterinary literature have responded to immunosuppressive medication but the prognosis generally is considered poor with a reported mortality rate of 80%. Reported response rates to immunosuppression alone in affected people are low with overall and complete responses of 65 and 10%, respectively. With the addition of eltrombopag, an orally available thrombopoietin receptor agonist, reported overall and complete response rates in people increase to 94 and 58%, respectively. Herein, we report the use of eltrombopag in a dog with idiopathic aplastic pancytopenia. Eltrombopag was started after no response was seen to treatment with prednisolone and cyclosporine. Complete remission was achieved after the addition of eltrombopag and was sustained after stopping the medication.

中文翻译：

---

Eltrombopag治疗特发性再生障碍性全血细胞减少症的狗。

特发性再生障碍性全血细胞减少症是犬中不常见的疾病，可导致全血细胞减少症，并怀疑是免疫介导的病因。兽医文献中报道的少数患病犬对免疫抑制药物有反应，但通常认为预后较差，据报道死亡率为80％。据报道，受影响人群仅对免疫抑制的应答率很低，总体和完全应答分别为65％和10％。据报告，口服可与之结合的血小板生成素受体激动剂Eltrombopag可使患者的总体和完全缓解率分别提高到94％和58％。在本文中，我们报道了Eltrombopag在特发性再生障碍性全血细胞减少症的狗中的使用。在用泼尼松龙和环孢霉素治疗未见反应后，开始使用Eltrombopag。加入Eltrombopag后可完全缓解，并在停药后持续缓解。